Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)-Reference-Cited by-同舟云学术

Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)

Published:2016-07 Issue:10041 Volume:388 Page:248-257
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Uesaka Katsuhiko,Boku Narikazu,Fukutomi Akira,Okamura Yukiyasu,Konishi Masaru,Matsumoto Ippei,Kaneoka Yuji,Shimizu Yasuhiro,Nakamori Shoji,Sakamoto Hirohiko,Morinaga Soichiro,Kainuma Osamu,Imai Koji,Sata Naohiro,Hishinuma Shoichi,Ojima Hitoshi,Yamaguchi Ryuzo,Hirano Satoshi,Sudo Takeshi,Ohashi Yasuo

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer;Neoptolemos;N Engl J Med,2004

2. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial;Oettle;JAMA,2007

3. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer;Ueno;Br J Cancer,2009

4. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial;Neoptolemos;JAMA,2010

5. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;Oettle;JAMA,2013

Cited by 848 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preoperative nutritional status is a useful predictor of the feasibility of postoperative treatment in octogenarian-plus pancreatic ductal adenocarcinoma patients;European Journal of Surgical Oncology;2024-12

2. Evaluation of a new scoring system for assessing nerve invasion in resected pancreatic cancer: A single-center retrospective analysis;Cancer Letters;2024-10

3. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells;Cancer Chemotherapy and Pharmacology;2024-09-14

4. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection following preoperative chemoradiotherapy;PLOS ONE;2024-09-06

5. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy;Pancreatology;2024-09